Entheon Biomedical Corp., a Canada-based biotech R&D entity, is focused on establishing psychedelic-related therapies with the help of DMT and commercialising its treatments to known physicians and clinics. The main business area of this company is psychedelic therapeutics, and the whole target market. Whereas, Nutravisor Inc. is known for generating a valuable portfolio of Nixodine™ and nutraceutical pouches. The company also produce on-demand products that serves best in class care to the individuals.
Nutravisor and Entheon signed a partnership agreement encompassing a business combination. Yesterday, both companies confirmed their business combination agreement that also includes a ‘three-cornered’ fusion of Nutravisor along with its wholly owned division of Entheon, known as ‘Subco’. This partnership will impact the outstanding and issued common shares of Nutravisor taken by Entheon, which will turn into a reverse takeover of Entheon.
According to the proposed transaction, there will be an important change by the company, as mentioned by the Canadian Securities Exchange (CSE). Adhering to CSE, this whole partnership deal and shares scenario, the Closing that brings the issuer to acquire conditional approval should register its common shares on the CSE. Regarding these shares' relation colliding with the partnership transaction, Entheon first needs to file a 2A Listing Statement with the CSE, obeying the policies of the CSE.
The implementation of the Business Combination Agreement follows the page of plans that was brought into light on 22nd December, 2025, by Entheon. The terms and conditions of this partnership deal explain the Proposed Transaction, which will be framed according to the ‘three-cornered amalgamation’ harnessed to the provision of the Business Corporations Act (Ontario), including all the participating entities in this agreement.
As per this deal, Entheon will centralise its outstanding and issued common shares under the post-Consolidation common share for 6.93 each pre-Consolidation Entheon shares. The share ratio will be fixed as per both companies' discussion. Alongside, Nutravisor is also planning to complete as much equity financing as possible to earn more profit and fix the share ratio at a reasonable price.
Subco and Nutravisor will be integrating with the Business Corporations Act, after which, together, the ‘Amalco’ will become an entire division of Entheon. This will strengthen this partnership at first place. After all the formalities, the Resulting Issuer will introduce a new name as per the mutual decision from both entities' ends.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
